Selank: Side Effects & Safety

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analog of the endogenous immunomodulatory tetrapeptide tuftsin, developed by the Russian Academy of Medical Sciences and the Institute of Molecular Genetics in the 1990s. It is approved in Russia for generalized anxiety disorder and neurasthenia. The key safety story for Selank is what it does not do compared with the standard-of-care for anxiety in the West: it produces no sedation, no cognitive impairment, no tolerance, and no withdrawal.^[1]

Selank is not on the agenda for the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list review (which covers BPC-157, TB-500, KPV, MOTS-c, DSIP/Emideltide, Epitalon, and Semax). Selank is not FDA-approved in the US. See our legal status guide for current US regulatory context.

Frequencies below are pooled from Russian clinical trials and post-market surveillance.^[2]

Effect	Frequency	Route	Notes
Mild nasal irritation / dryness	Common (~5–10%)	Intranasal	Typically adapts within first week
Bitter taste / post-nasal drip	Common	Intranasal	Normal nasal absorption; harmless
Mild injection-site redness	Common at site	Subcutaneous	Rotate sites
Transient headache (initial use)	Uncommon (<5%)	Both	Resolves within first few days
Sedation	Not reported	Both	Unlike benzodiazepines, Selank does not impair alertness
Cognitive impairment	Not reported	Both	Selank improves rather than impairs working memory
Tolerance / dependence / withdrawal	Not observed	Both	No GABAergic action; no documented withdrawal syndrome
Allergic reaction	Rare (<1%)	Both	Discontinue and seek evaluation

Russian toxicology dossiers reported no mutagenic, teratogenic, or carcinogenic signal at clinical doses. Acute LD50 in animal studies was very high, consistent with the broader pattern of low-toxicity for short peptides.

The clinical interest in Selank centers on producing anxiolytic effects comparable to medazepam (a Russian-prescribed benzodiazepine) without the safety liabilities of benzodiazepines. Published comparative data shows:

• No sedation: Selank does not produce drowsiness, slowed reaction time, or impaired coordination — the dominant safety concern with benzodiazepines (especially in older adults and drivers).
• No cognitive impairment: Working memory and attention measures are preserved or improved with Selank, in contrast to clinically meaningful impairment from benzodiazepines.
• No tolerance: repeated Selank dosing does not require dose escalation to maintain effect.
• No dependence or withdrawal: abrupt discontinuation does not produce the rebound anxiety, insomnia, or seizure risk seen with chronic benzodiazepine use.
• No respiratory depression: Selank does not act on GABA-A receptors and lacks the respiratory depression risk of benzodiazepines (especially when combined with opioids or alcohol).

This safety differential is the primary scientific rationale for Selank research. It does not mean Selank is safe in absolute terms — it means it avoids the specific failure modes of benzodiazepines.

• Pregnancy and breastfeeding: no controlled human safety data. Contraindicated.
• Known hypersensitivity to tuftsin-derived peptides or any formulation excipient.
• Active autoimmune disease: Selank's tuftsin origin gives it mild immunomodulatory activity. Theoretical caution in active lupus, multiple sclerosis flare, or other active autoimmune disease. Discuss with your rheumatologist or treating specialist before use.
• Severe psychiatric disorders requiring acute pharmacotherapy: Selank is not a substitute for first-line treatment of major depression, severe anxiety, psychosis, or PTSD.
• Pediatric use: some Russian protocols exist; not advisable outside pediatric supervision.

Drug interactions

• Benzodiazepines, opioids, alcohol: no documented dangerous interaction. Selank is non-sedating so does not compound CNS depression — but mixing with these substances is still poor practice for unrelated reasons.
• SSRIs and SNRIs: no known clinically significant interaction. Selank has been studied as an adjunct in Russian protocols.
• Stimulants and modafinil: no known interaction; theoretical additive effect on attention.
• Immunosuppressants: theoretical opposition of effect due to Selank's mild immunomodulatory activity.

• Nasal irritation: reduce concentration, alternate nostrils, saline rinse before dosing.
• Initial headache: reduce dose by 50% for 2–3 days, then return to standard dose.
• Persistent fatigue or mood change: uncommon; discontinue and evaluate other causes.
• New autoimmune symptoms during use: discontinue and consult your rheumatologist.
• Allergic reaction (rash, hives, breathing difficulty): discontinue immediately and seek emergency care.

See the Selank complete guide, dosage protocols, benefits and research, and Selank vs Semax comparison.